Market: NASD |
Currency: USD
Address: 999 West Broadway
ESSA Pharma Inc., a clinical stage pharmaceutical company, focuses the development of small molecule drugs for the treatment of prostate cancer. The company's lead candidate EPI-7386, an androgen receptor based resistance mechanisms that develop in patients with castration-resistant prostate cancer and metastatic castration-resistant prostate cancer. It has collaboration agreements with Bayer Consumer Care AG; Janssen Research & Development, LLC; and Astellas Pharma Inc. ESSA Pharma Inc. was incorporated in 2009 and is headquartered in Vancouver, Canada.
📈 ESSA Pharma Inc. Historical Chart
📊 Statistics
-
Analyst 1 Year Price Target:
-
-
Upside/Downside from Analyst Target:
-
-
Broker Call:
-
-
Dividend Minimum 3 Year Yield:
0.00%
-
EPS Growth Range (1Y):
0-10%
-
Net Income Growth Range (1Y):
0-10%
-
Revenue Growth Range (1Y):
-
-
Upcoming Earnings Date:
2025-12-16
-
EPS Estimate:
-0.23
💰 Dividend History
| Year |
Annual Yield (%) |
Total Amount |
Current Yield (%) |
Ex Date |
Pay Date |
Particulars |
| 2018 |
- |
$0.050000 |
- |
2018-04-25 |
- |
Stock split |
|
Total Amount for 2018: $0.050000 |
📅 Earnings & EPS History for ESSA Pharma Inc.
| Date | Reported EPS |
|---|
| 2025-12-16 (estimated upcoming) | - |
| 2025-05-08 | -0.19 |
| 2025-02-11 | -0.27 |
| 2024-12-17 | -0.2 |
| 2024-08-05 | -0.22 |
| 2024-05-14 | -0.27 |
| 2024-02-13 | -0.19 |
| 2023-12-12 | -0.16 |
| 2023-08-08 | -0.23 |
| 2023-05-09 | -0.21 |
| 2023-02-07 | -0.2 |
| 2022-12-13 | -0.19 |
| 2022-08-04 | -0.26 |
| 2022-05-10 | -0.32 |
| 2022-02-03 | -0.27 |
| 2021-11-18 | -0.25 |
| 2021-08-16 | -0.26 |
| 2021-05-06 | -0.44 |
| 2021-02-11 | -0.25 |
| 2020-12-15 | -0.22 |
| 2020-08-05 | -0.32 |
| 2020-05-07 | -0.63 |
| 2020-02-12 | -0.29 |
| 2019-12-19 | -0.3 |
| 2019-08-14 | -0.69 |
📰 Related News & Research
No related articles found for "essa pharma".
